REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
03/10/2024 09:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241003:nRSC8297Ga&default-theme=true
RNS Number : 8297G MaxCyte, Inc. 03 October 2024
MaxCyte, Inc.
("MaxCyte" or the "Company")
Exercise of options and PDMR dealing
ROCKVILLE, MD, October 3, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and to support innovative, cell-based
research, announces that between 1 October 2024 and 2 October 2024, as per a
filing lodged with the U.S. Securities and Exchange Commission, Stanley Erck,
a Non-Executive Director of the Company, exercised options over 47,689 shares
of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in
aggregate. The 47,689 new shares of Common Stock were issued pursuant to the
Company's existing its block admission facility and were sold by Stanley
Erck at a price range between $3.625 and $3.880 per Common Stock ("Sale").
The sold shares represent approximately 7.94% of Stanley Erck's total equity
and option holdings in the Company's stock capital, respectively.
Following the Exercise and Sale, Stanley Erck holds 247,751 shares of Common
Stock representing 0.2% of the issued stock capital of the Company. Following
the Exercise, Stanley Erck holds a further 324,190 options over Common Stock
and 21,367 restricted stock units.
The sales and option exercises were effected pursuant to a Rule 10b5-1 trading
plan adopted by Stanley Erck on 12 March 2024 relating solely to the sale of
shares acquired from exercise of options that expire on 11 November 2024.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com (mailto:ir@maxcyte.com)
Nominated Adviser and Joint Corporate Broker
Panmure Liberum +44 (0)20 7886 2500
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
UK IR Adviser +44 (0)203 709 5700
ICR Consilium maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)
Mary-Jane Elliott
Chris Welsh
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com (https://maxcyte.com/) and follow us on X
(https://twitter.com/MaxCyte_info) (formerly Twitter) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Exercise of Options over common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$0.040 26,082
d) Aggregated information
- Aggregated volume 26,082
- Price $0.040
e) Date of the transaction 1 October 2024
f) Place of the transaction US Stock Exchange, Nasdaq
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Sale of common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$3.6900 200
$3.6950 1301
$3.7000 200
$3.7050 1600
$3.7100 100
$3.7150 900
$3.7200 466
$3.7300 1001
$3.7350 1666
$3.7400 200
$3.7450 800
$3.7500 349
$3.7550 975
$3.7650 2700
$3.7700 700
$3.7750 1700
$3.7800 104
$3.7850 1000
$3.7950 1200
$3.8000 200
$3.8050 200
$3.8150 1600
$3.8200 200
$3.8250 700
$3.8300 607
$3.8350 300
$3.8400 200
$3.8450 1500
$3.8500 300
$3.8600 600
$3.8650 713
$3.8700 1000
$3.8750 100
$3.8800 500
d) Aggregated information
- Aggregated volume 26,082
- Price $3.7784
e) Date of the transaction 1 October 2024
f) Place of the transaction US Stock Exchange, Nasdaq
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Exercise of Options over common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$0.040 21,607
d) Aggregated information
- Aggregated volume 21,607
- Price $0.040
e) Date of the transaction 2 October 2024
f) Place of the transaction US Stock Exchange, Nasdaq
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Sale of common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$3.6250 400
$3.6300 200
$3.6350 109
$3.6400 300
$3.6450 50
$3.6500 13
$3.6550 50
$3.6600 200
$3.6650 200
$3.6700 400
$3.6750 305
$3.6800 1078
$3.6850 525
$3.6900 1700
$3.7000 1037
$3.7100 240
$3.7150 1040
$3.7200 9400
$3.7210 900
$3.7250 251
$3.7400 467
$3.7500 142
$3.7650 100
$3.7700 2500
d) Aggregated information
- Aggregated volume 21,607
- Price $3.7131
e) Date of the transaction 2 October 2024
f) Place of the transaction US Stock Exchange, Nasdaq
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEAPEDELELFEARecent news on MaxCyte
See all newsREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - First Quarter 2025 Financial Results
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Total Voting Rights
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Filing of definitive proxy statement
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
Announcement